Patient and Physician Knowledge of Key Safety Messages

Bayer

Status: Completed

Conditions: Anticoagulation

Treatments: Behavioral: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01907048

XA1202 (Other Identifier)

16167

Details and patient eligibility

About

This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.

Enrollment: 2,227 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Inclusion criteria:

Physician eligibility:

• Prescription of rivaroxaban in the past 6 months for adult patients for the Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (SPAF) or Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT.

Patient eligibility:

• Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and above; able to understand and complete the consent form and patient questionnaire.

Trial design

2,227 participants in 2 patient groups

Group 1

Description:

Survey to measure physician awareness and understanding of the key messages in the prescriber guide.

Treatment:

Behavioral: Rivaroxaban (Xarelto, BAY59-7939)

Behavioral: Rivaroxaban (Xarelto, BAY59-7939)

Group 2

Description:

Survey to measure patient awareness and understanding of the key messages in the patient card.

Treatment:

Behavioral: Rivaroxaban (Xarelto, BAY59-7939)

Behavioral: Rivaroxaban (Xarelto, BAY59-7939)